Literature DB >> 7654217

Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes.

C V Oddis1, M S Finkel.   

Abstract

We have previously proposed that cytokine-stimulated nitric oxide (NO) production is responsible for reversible myocardial depression in sepsis, trauma and ischemia. NO previously has been found to inhibit mitochondrial activity in other cell types. Accordingly, we sought to determine if cytokine-stimulated NO production inhibited cardiac myocyte mitochondrial activity. Treatment of neonatal rat cardiac myocytes with interleukin-beta (IL-1) resulted in the expression of mRNA for inducible NO synthase (iNOS) and stained positively for iNOS protein by immunohistochemistry. No iNOS staining was detected in untreated cells. IL-1 treatment resulted in significant nitrite levels vs control over 48 hrs (4.2 +/- 0.7 vs 0.3 +/- 0.2 nmol/1.25 x 10(5) cells, respectively) (n = 12) that was inhibited by 1mM NMA (0.3 +/- 0.2 nmoles; p < .01; n = 12). Mitochondrial activity was assessed by the MTT colorimetric assay using (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and OD 570-630. Mitochondrial activity was significantly inhibited by IL-1 vs control cells (0.436 +/- 0.01 vs 0.608 +/- 0.03) and reversed by 1mM NMA (0.549 +/- 0.03) or removal of IL-1 (0.662 +/- 0.02) (p < .01; n = 12 for each). These data strongly suggest that cytokine-stimulated NO production by cardiac myocytes results in reversible inhibition of mitochondrial activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654217     DOI: 10.1006/bbrc.1995.2228

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Heart mitochondria signaling pathways: appraisal of an emerging field.

Authors:  José Marín-García; Michael J Goldenthal
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

Review 2.  Cardiac dysfunction in sepsis: new theories and clinical implications.

Authors:  R M Grocott-Mason; A M Shah
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 3.  The role of nitric oxide in the failing heart.

Authors:  W J Paulus
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

Review 4.  Interactions between cytokines and neurohormonal systems in the failing heart.

Authors:  H Kan; M S Finkel
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

5.  Inducible nitric oxide synthase in the myocard.

Authors:  I B Buchwalow; W Schulze; P Karczewski; M M Kostic; G Wallukat; R Morwinski; E G Krause; J Müller; M Paul; J Slezak; F C Luft; H Haller
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

Review 6.  Proinflammatory cytokines in heart failure: double-edged swords.

Authors:  Mona Hedayat; Mohammad Jafar Mahmoudi; Noel R Rose; Nima Rezaei
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

7.  Both cGMP and peroxynitrite mediate chronic interleukin-6-induced negative inotropy in adult rat ventricular myocytes.

Authors:  Xin-Wen Yu; Meei-Yueh G Liu; Richard H Kennedy; Shi J Liu
Journal:  J Physiol       Date:  2005-05-05       Impact factor: 5.182

8.  Metabolomic profiling of cellular responses to carvedilol enantiomers in vascular smooth muscle cells.

Authors:  Mingxuan Wang; Jing Bai; Wei Ning Chen; Chi Bun Ching
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

9.  Interleukin-1 beta and tumor necrosis factor-alpha inhibit the release of [3H]-noradrenaline from mice isolated atria.

Authors:  S Foucart; C Abadie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

10.  Deficient BH4 production via de novo and salvage pathways regulates NO responses to cytokines in adult cardiac myocytes.

Authors:  Irina A Ionova; Jeannette Vásquez-Vivar; Jennifer Whitsett; Anja Herrnreiter; Meetha Medhora; Brian C Cooley; Galen M Pieper
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-03       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.